捷克 SOTIO, 舒迪安,  
舒迪安舒迪安是一家生物技术公司，致力于开发基于活化树突状细胞的新治疗方法，主要专注癌症和自体免疫性疾病的治疗。我们的使命是采用基于我们自有知识产权的细胞技术来开发新的治疗方法，并通过我们自有的免疫疗法平台应对很大程度上未得到满足的医疗需求。

一大批世界知名科学家聚集在舒迪安公司位于布拉格的研究中心，，他们借助于目前最尖端的实验设备积极探索树突状细胞在免疫反应活化治疗中的应用。

舒迪安公司通过下列方式开发最新治疗方法：
采用自体细胞免疫疗法治疗癌症和自体免疫疾病
采用免疫疗法连同化疗等其他标准治疗方式提高临床疗效
研究免疫疗法的长期治疗效果以增强免疫系统对特定疾病的反应能力
使用广谱的肿瘤抗原，通过患者自身树突状细胞的活化，来刺激复杂的免疫反应
我公司的临床开发方案旨在采用活化树突状细胞免疫疗法，为某些特定的、现有治疗手段匮乏的部分疾病拓展治疗选择。

先期通过我公司的免疫疗法平台实施的针对前列腺癌晚期病人的临床试验，显示出了令人鼓舞的实验效果。我们计划2012年在全球范围内开展三期验证性临床研究，旨在为可选治疗方案有限的患者提供此种疗法。

舒迪安公司建立了设施最先进并且是欧洲最大规模之一的研发和细胞产品制备中心，符合最新的优质生产标准（GMP），所生产的基于细胞的医疗产品均符合全球最高监管标准。舒迪安公司的研发和生产基地位于布拉格，这一地理位置有利于我公司产品在整个欧洲范围内的快速流通

SOTIO is a biotechnology company developing new therapies based on activated dendritic cells, focusing on the treatment of cancer and autoimmune diseases. Our mission is to develop new medical therapies using our proprietary cell-based technologies to treat highly unmet medical conditions using our immunotherapy platform.

World renowned scientists are working at Sotio's research facilities in Prague using state-of-the art technologies to understand the role of dendritic cells in the therapeutic activation of the body's immune response.

Implementing autologous cellular immunotherapy approaches for the treatment of cancer and autoimmune diseases
Utilizing immunotherapy combined with other standard treatment modalities such as chemotherapy to improve clinical outcomes
Investigating the effect of long-term treatment with immunotherapy to enhance the immune system's response to a particular disease
Using a wide spectrum of tumor antigens to induce a complex immune response through activation of a patient's own dendritic cells.
Our clinical development programs are designed to use activated dendritic cell immunotherapy to expand treatment options targeting those diseases where few treatment alternatives exist.

Early clinical trials in advanced stage prostate cancer have shown promising preliminary results using our proprietary immunotherapy platform. We are planning on initiating confirmatory phase III worldwide clinical studies in 2012 with the aim of offering this therapy to those patients who have limited options.

SOTIO's therapies are produced in a state-of-the-art good manufacturing practices (GMP) cell therapy manufacturing facility that is among the largest in Europe. Our cell manufacturing facility meets the highest regulatory standards world-wide for the production of cellular based medicinal products. The facility's location in Prague expedites the transport of our products throughout Europe.